BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nanoformulated indomethacin: Phase II data

A double-blind Phase II trial in 203 patients aged 18-50 who had at >=2 third molars extracted showed that indomethacin in nanoformulated doses of 20 and 40 mg each met the primary endpoint of significantly improving mean TOTPAR scores over 8 hours vs. placebo (10.8 and 12.6 points, respectively, vs. 3 points;...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >